Skip to content
phase 2Cardiovascular

Atrial Natriuretic Peptide (ANP)

Also known as: Atrial Natriuretic Factor, ANF, ANP, Atriopeptin, Cardionatrin, Atrial Natriuretic Hormone

Atrial Natriuretic Peptide (ANP) is a 28-amino acid endogenous cardiac hormone secreted primarily by atrial cardiomyocytes in response to atrial distension from increased blood volume. ANP was the first natriuretic peptide discovered in 1981 and plays a central role in blood pressure and fluid volume homeostasis through natriuresis, diuresis, and vasodilation. It counterbalances the renin-angiotensin-aldosterone system and is under investigation as a therapeutic agent for heart failure, hypertension, and renal protection.

4 cited references·6 researched benefits

Quick Answer

Atrial Natriuretic Peptide (ANP) is a 28-amino acid hormone released by heart atrial cells when stretched by excess blood volume. It lowers blood pressure by promoting sodium and water excretion through the kidneys, dilating blood vessels, and suppressing aldosterone. ANP was the first natriuretic peptide discovered and is being studied in phase 2 trials for heart failure and acute kidney injury treatment.

Key Facts

Mechanism
ANP is stored in atrial granules as proANP and released upon atrial wall stretch from volume overload. The 28-amino acid active peptide binds natriuretic peptide receptor A (NPR-A), activating particulate guanylate cyclase and raising intracellular cGMP. Downstream effects include: vasodilation of afferent and efferent renal arterioles increasing glomerular filtration rate; direct inhibition of sodium reabsorption in the collecting duct; suppression of renin release from juxtaglomerular cells; inhibition of aldosterone synthesis in the adrenal cortex; and reduction in sympathetic nervous system activity. ANP is degraded by neutral endopeptidase (neprilysin) and cleared via NPR-C receptor internalization.
Research Status
phase 2
Half-Life
~2-5 minutes
Molecular Formula
C₁₂₇H₂₀₃N₃₅O₄₀S₃
Primary Use
Cardiovascular
Table of Contents

Benefits

  • Potent natriuresis and diuresis — increases renal sodium and water excretion to reduce blood volumestrong
  • Vasodilation — reduces systemic vascular resistance and lowers blood pressurestrong
  • RAAS suppression — inhibits renin and aldosterone secretion to reduce fluid retentionstrong
  • Renal protection — low-dose ANP infusion may reduce acute kidney injury risk after cardiac surgerymoderate
  • Anti-fibrotic and anti-hypertrophic effects on cardiac tissuemoderate
  • Metabolic benefits — promotes lipolysis and adipose tissue browning in preclinical modelspreliminary

Dosage Protocols

RouteDosage RangeFrequencyNotes
Intravenous infusion (investigational)0.01-0.05 mcg/kg/minContinuous infusion for 24-72 hoursPhase 2 studies in acute heart failure and post-cardiac surgery renal protection. Low-dose infusion (0.02 mcg/kg/min) preferred to minimize hypotension.
Subcutaneous injection (investigational)1-5 mcg/kgMultiple times daily (limited by short half-life)Short half-life (~2-5 minutes) severely limits subcutaneous utility. Sustained-release formulations under development.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Hypotension, especially at higher infusion ratescommon
  • Excessive diuresis leading to dehydrationcommon
  • Headache during exogenous infusioncommon
  • Symptomatic hypotension requiring dose reduction or vasopressor supportserious
  • Electrolyte imbalances (hyponatremia, hypokalemia)rare

Frequently Asked Questions

What is the difference between ANP and BNP?
ANP (28 amino acids) is primarily released from atrial cardiomyocytes in response to atrial stretch from volume overload, while BNP (32 amino acids) is primarily released from ventricular cardiomyocytes in response to ventricular wall stress. Both act through the same NPR-A receptor to produce natriuresis and vasodilation. ANP has a much shorter half-life (~2-5 minutes vs ~20 minutes for BNP). Clinically, BNP and NT-proBNP are the preferred diagnostic biomarkers for heart failure because ventricular dysfunction is the primary pathology, and BNP levels more reliably reflect disease severity.
Why is ANP important in blood pressure regulation?
ANP is a critical counter-regulatory hormone that opposes the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system. When blood volume increases and stretches the atria, ANP release causes the kidneys to excrete more sodium and water, dilates blood vessels, and suppresses aldosterone — all of which lower blood pressure. Genetic variants affecting ANP levels are associated with hypertension risk, and the drug Entresto works partly by preventing ANP degradation. ANP dysfunction contributes to the pathophysiology of heart failure, hypertension, and salt-sensitive blood pressure disorders.
Can ANP be used as a heart failure treatment?
Exogenous ANP infusion has been tested in phase 2 clinical trials for acute decompensated heart failure and post-cardiac surgery renal protection, primarily in Japan where carperitide (recombinant ANP) was approved for acute heart failure. However, its extremely short half-life (~2-5 minutes) requires continuous intravenous infusion, which limits practical use. Instead, the neprilysin inhibitor sacubitril (in Entresto) works by blocking the enzyme that degrades endogenous ANP and BNP, effectively raising their levels to provide chronic benefit. This indirect approach has proven more clinically practical.
What role does ANP play in the metabolic system?
Research increasingly recognizes ANP as a metabolic hormone beyond its cardiovascular role. Natriuretic peptides activate lipolysis in adipose tissue through cGMP-dependent protein kinase (PKG) signaling, promote white-to-brown fat conversion (browning), increase mitochondrial biogenesis, and enhance fatty acid oxidation. Low ANP levels are associated with metabolic syndrome, insulin resistance, and type 2 diabetes. Exercise-induced ANP release may contribute to the metabolic benefits of physical activity. These findings have sparked interest in natriuretic peptide-based approaches for metabolic disease.

References

  1. 1
    A new potent natriuretic and vasorelaxant peptide from human atria (initial discovery)(1984)PubMed ↗
  2. 2
    Atrial natriuretic factor: a hormone produced by the heart(1988)PubMed ↗
  3. 3
    Carperitide (recombinant ANP) for acute heart failure: clinical evidence from Japanese trials(2008)PubMed ↗
  4. 4
    Natriuretic peptides in metabolic regulation: role in obesity and diabetes(2012)PubMed ↗

Latest Research

Last updated: 2026-02-19